The recently published outcomes of the ProtecT trial showed no difference in PCa-specific survival after a median of 10 yr follow-up between surgery (RP), radiotherapy (RT) and active monitoring (AM) in men with screen detected localized prostate cancer (PCa) [1]. However, data also showed a higher rate of metastatic (Mþ) PCa in the AM arm. Caveat of ProtecT are the randomization of PCa cases into the AM arm that are considered high risk and the AM protocol which is substantially different from current Active Surveillance (AS) protocols.
INTRODUCTION AND OBJECTIVES:
The recently published outcomes of the ProtecT trial showed no difference in PCa-specific survival after a median of 10 yr follow-up between surgery (RP), radiotherapy (RT) and active monitoring (AM) in men with screen detected localized prostate cancer (PCa) [1] . However, data also showed a higher rate of metastatic (Mþ) PCa in the AM arm. Caveat of ProtecT are the randomization of PCa cases into the AM arm that are considered high risk and the AM protocol which is substantially different from current Active Surveillance (AS) protocols.
METHODS: From men diagnosed with PCa at the 1st and 2nd screening round of ERSPC Rotterdam (1993 Rotterdam ( -2003 considered suitable for AS (i.e Gleason score 3þ3, T2a PCa cases), we calculated PCaspecific survival and rate of Mþ PCa and compared these outcomes between men treated with AS predominantly according to the PRIAS protocol (n¼223), having had a RP (N¼365) or treated with RT (n¼312).
RESULTS: Baseline characteristics are listed in Table 1 and reflect the non-randomized setting. However, statistically significant differences do not automatically translate to clinically relevant differences. After a median follow-up of 15-yr (IQR 12-17 yr), 18 men died from PCa. Similar to ProtecT, no significant difference in PC specific survival was found between AS (97.2%; 95% CI: 94.7-99.7), RP (98.5%; 95% CI: 97.2-99.8), and RT (97.5%; 95% CI: 95.5-99.5), logrank p¼0.36. However, contrary to ProtecT, Mþ-free survival was also similar with rates of 96.9% (95% CI: 94.4-99.4) for AS, 97.9% (95% CI: 96.3-99.5) for RP and 96.6% (95% CI: 94.4-99.0) for RT, log-rank p¼0.42 (Table 2) . CONCLUSIONS: The current data support a comparable long-term risk of disease progression of low-risk PCa in men initially treated with AS according to a protocol including regular monitoring with PSA, DRE and prostate biopsy and men opting for immediate active treatment. Personal preferences including considerations on quality of life will become more and more important in the treatment decision of low-risk PCa. INTRODUCTION AND OBJECTIVES: DNA repair gene mutations are important molecular alterations in prostate cancer pathogenesis. Germline mutations in DNA repair genes, particularly BRCA2, were recently recognized as associated with metastatic prostate cancer. Prostate tumors with DNA repair defects may also be particularly sensitive to platinum based chemotherapy and PARP inhibitor therapy. We sought to characterize alterations in DNA repair pathway genes in both primary and metastatic prostate tumors.
METHODS: We studied the distribution of DNA repair gene mutations in 936 prostate cancers harvested from localized and metastatic tumors. Tumor DNA underwent hybrid capture for all coding exons of 395 cancer-related genes plus select introns from 19 or 31 genes frequently rearranged in cancer. Captured libraries were sequenced to a median exon coverage depth of >500x using Illumina sequencing and were analyzed for base substitutions/insertions, copy number alterations and rearrangements. We utilized two described lists of genes involved in DNA repair : our own in-house list of 74 (UCD) and a list of 20 DNA repair genes associated with cancer predisposition syndromes utilized in a recent publication by Pritchard et al. Nine genes were in common between the two lists yielding a total of 85 unique DNA repair genes. We further stratified the frequency of mutations by tissue site (prostate versus metastases). Only tissues represented by at least 10 samples in the set were included (868). Frequencies of DNA repair e56 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 
